Tag Archives: ALNY

Hot Biotech Stocks To Watch For 2022

Investors in the Biotech industry have had a rough few weeks. The benchmark SPDR S&P Biotech ETF (NYSEARCA:XBI)has fallen 26% since peaking in February of this year. However, Atossa Therapeutics (NASDAQ:ATOS) stock seems to have bucked the overall biotech bearish trend.

Source: luchschenF / Shutterstock.com

Despite the steep drop from all-time highs of $9, ATOS stock is still up for the year, trading around $3.50 today. That’s up about 270% since the beginning of this year and right with its 200-day moving average of $3.

The question is whether ATOS stock is still a good investment at these levels.

Hot Biotech Stocks To Watch For 2022: ArQule Inc.(ARQL)

ArQule, Inc., a clinical-stage biotechnology company, engages in the research and development of cancer therapeutics directed toward molecular targets and biological processes. Its lead product ARQ 197 is non-adenosine triphosphate competitive inhibitor of the c-Met receptor tyrosine kinase, which is being evaluated as monotherapy and in combination therapy in a Phase II clinical development program that includes trials in non-small cell lung cancer, c-Met-associated soft tissue sarcomas, pancreatic adenocarcinoma, hepatocellular carcinoma, germ cell tumors, and colorectal cancer. The company is also developing ARQ 621, a Phase I program focused on inhibition of the Eg5 kinesin spindle protein. Its clinical stage products include ARQ 501, ARQ 761, and ARQ 171, which are designed to kill cancer cells selectively while sparing normal cells through the direct activation of DNA damage response/checkpoint pathways. In addition, the company involves in pre-clinical development o f B-RAF and AKIP Kinase inhibitors. The company has collaborations with Kyowa Hakko Kirin Co., Ltd. and Daiichi Sankyo Co., Ltd. ArQule, Inc. was founded in 1993 and is headquartered in Woburn, Massachusetts.

Advisors’ Opinion:

  • [By Cory Renauer]

    It isn’t unusual for oncology stocks to double in a single day after a company announces clinical trial results. Arqule (NASDAQ:ARQL) stands out among its peers because it notched a 67% gain after reporting a partial remission for just one leukemia patient.

  • [By Motley Fool Transcribers]

    Arqule Inc (NASDAQ:ARQL)Q42018 Earnings Conference CallMarch 07, 2019, 9:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Dan Caplinger]

    Thursday was another down day for the stock market, with new pressure coming from international moves on the macroeconomic front. The European Central Bank signaled that it was ready to provide more accommodative monetary policy, reversing a previous tightening stance and showing its concerns about the prospects for economic growth in the region. Yet favorable earnings reports continued lifting shares of certain individual companies. Rosetta Stone (NYSE:RST), ArQule (NASDAQ:ARQL), and Fly Leasing (NYSE:FLY) were among the top performers. Here’s why they did so well.

  • [By Maxx Chatsko]

    Shares of ArQule (NASDAQ:ARQL) rose over 70% today after the company reported full-year 2018 operating results and provided full-year 2019 guidance. That said, investors are probably used to wild swings in the stock price by now. The development-stage pharma didn’t turn in a particularly impressive performance last year. Management expects revenue to drop significantly in the year ahead as collaboration revenue dries up, which will also widen operating losses.

Hot Biotech Stocks To Watch For 2022: Biogen Idec Inc(BIIB)

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Its marketed products include the AVONEX for the treatment of relapsing multiple sclerosis (MS); RITUXAN for treating relapsed or refractory, CD20-positive, and B-cell Non-Hodgkin?s lymphoma (NHL); TYSABRI to treat relapsing MS; FUMADERM for the treatment of severe plaque psoriasis in adult patients; and FAMPYRA, an oral compound for the improvement of walking in adult patients with MS with walking disability. Biogen Idec Inc.?s products under Phase III consist of PEGylated interferon beta-1a designed to prolong the effects and reduce the dosing frequency of interferon beta-1a; BG-12 for the treatment of MS; Daclizumab, a monoclonal antibody in relapsing MS; Long-lasting factor IX and VIII fusion protein for the treatment of hemophilia B; GA101, a monoclonal antibody for t he treatment of chronic lymphocytic leukemia and NHL; and Dexpramipexole, an orally administered small molecule for the treatment of amyotrophic lateral sclerosis. The company?s Phase I clinical trial products include Anti-LINGO for use in multiple sclerosis, Neublastin for use in neuropathic pain, CD40L for use in systemic lupus erythematosus, ANTI-TWAEK humanized monoclonal antibody for TWEAK, and BIIB037 for use in Alzheimer’s disease; and Phase II clinical trial product comprises OCRELIZUMAB, a humanized monoclonal antibody for treating CD20. It has collaboration agreements with Genentech, Inc.; Elan Pharma International, Ltd; Acorda Therapeutics, Inc.; Portola Pharmaceuticals, Inc.; Swedish Orphan Biovitrum AB; Abbott Biotherapeutics Corp; and Vernalis plc. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Weston, Massachusetts.

Advisors’ Opinion:

  • [By ]

    Just last Thursday, March 21, Biogen (Nasdaq: BIIB) and its partner, Japanese biopharmaceutical company Eisai (OTC: ESALY), said that their experimental Alzheimer’s therapy, which at that time was at the second stage of clinical trials, was a bust. BIIB dropped 29.2% on the day, and ESALY by 35% on the same day.

  • [By Chris Hill]

    In this episode ofMotley Fool Money, host Chris Hill and analysts Emily Flippen, Jim Mueller, and Jason Moser hit on some of the biggest recent news in the market. Disney (NYSE:DIS)finishes up its merger with Fox, and it’s ready to take on a crowded streaming space. CVS Health(NYSE:CVS) diversifies into CBD lotion. Levi Strauss(NYSE:LEVI) enters the public markets with a bafflingly high market cap, while Nike (NYSE:NKE)sells off on higher-than-expected revenue and profits. Biogen’s (NASDAQ:BIIB) biggest trial bombs, and the stock tanks along with it. Papa John’s(NASDAQ:PZZA) welcomes Shaq into its board of directors. And, as always, the analysts share some stocks on their radar. Plus, stay tuned for an interview with Lake House Capital’s Joe Magyer about investing in Australia — the biggest trends, biggest worries, and some Aussie picks to add to your watch list.

  • [By Garrett Baldwin]

    Nike Inc. (NYSE: NKE) will lead a busy day of earnings reports. The firm expects that its year-over-year sales will have increased by 7%. The company’s stock slumped in February after Duke basketball player Zion Williamson was hurt blowing out his sneaker in the first minute of a major contest against North Carolina. Expect analysts to ask a lot of questions about Nike’s expectations for global economic growth and its exposure to a weakening Chinese economy.
    Stocks to Watch Today: BIIB, BA, LEVI
    Shares of Biogen Inc.(NASDAQ: BIIB) plunged more than 25% after the company announced a major setback for a key Alzheimer’s drug. The biotech giant announced that its experimental drug “aducanumab” is unlikely to be effective for mass deployment and that it will halt its research. One analyst described this as a “transformative failure for Biogen’s pipeline.” This is a massive setback for one of the top biotech companies in the world. Shares of Boeing Co. (NYSE: BA) are off again Thursday on news that the investigation into its 737 Max jets has expanded. According to reports, the FBI has now joined a federal investigation into the certification process for the jet. The Department of Transportation launched an audit of the Federal Aviation Administration’s approval of the jet, which received certification two years ago. Boeing and the FAA have faced global scrutiny over two fatal crashes involving the 737 Max jet series and news of previous pilot complaints about the planes. Levi Strauss & Co. (NYSE: LEVI) will return to the public markets for the first time in 34 years. The iconic apparel company will launch its IPO today with a price of $17 per share. That would set the company’s market capitalization at $6.6 billion. Look for other earnings reports from Canadian Solar Inc. (NASDAQ: CSIQ), Cintas Corp. (NASDAQ: CTAS), CNOOC Ltd. (NYSE: CEO), Conagra Brands Inc. (NYSE: CAG), Darden Restaurants Inc. (NYSE: DRI), and Lands’ End Inc. (NYSE: LE).
    Public Law 92-

Hot Biotech Stocks To Watch For 2022: Amgen Inc.(AMGN)

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Advisors’ Opinion:

  • [By ]

    That said, IBB is popular in part because its top holdings at present include Moderna (MRNA), Amgen (AMGN) and Gilead Sciences (GILD) three very mature and very profitable biotech companies that collectively add up to more than $370 billion in market value. This provides a good foundation for the smaller and more aggressive picks that supplement the portfolio of this healthcare ETF.

  • [By Motley Fool Staff]

    Every so often on Rule Breaker Investing, Motley Fool co-founder David Gardner shares a five-stock sampler — five active recommendations in either Rule Breakers or Stock Advisor that are poised for great things. This week: five healthcare companies that are innovating treatments and drugs that are making the world healthier. Learn more about Amgen (NASDAQ:AMGN), bluebird bio (NASDAQ:BLUE), Editas Medicine (NASDAQ:EDIT), Illumina (NASDAQ:ILMN), and Vertex Pharmaceuticals (NASDAQ:VRTX) and why you should add these exciting and inspiring stocks to your watch list.

  • [By ]

    Even though ABBV has more than 100 patents covering Humira, and despite its 2017 patent win over Amgen (Nasdaq: AMGN) requiring AMGN to wait until 2023 before issuing its own copy of Humira, the battle for generic Humira isn’t over.

  • [By Brian Feroldi]

    Amgen (NASDAQ:AMGN) andBiogen(NASDAQ:BIIB)have a lot in common. They are both hugely successful biotech giants that were founded decades ago. They each have produced stellar returns for their long-term shareholders and crank out copious amounts of cash flow each year.

Hot Biotech Stocks To Watch For 2022: Alnylam Pharmaceuticals Inc.(ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Advisors’ Opinion:

  • [By ]

    Advisors Asset Management Inc. cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 25.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,685 shares of the biopharmaceutical company’s stock after selling 1,232 shares during the quarter. Advisors Asset Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $625,000 as of its most recent SEC filing.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Cory Renauer]

    Staying on top of every new drugmaker takes a lot more time than you probably have. That said,Alnylam Pharmaceuticals (NASDAQ:ALNY)andPfizer (NYSE:PFE) shareholders want to keep their eyes on young Eidos and its lead candidate. Here’s why.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) updated investors last month on how the launch of Onpattro, its first drug that was approved to treat transthyretin-mediated amyloidosis (ATTR), was going at the J.P. Morgan Healthcare Conference.

Top Performing Stocks To Buy For 2022

When you think about it, just about every investor is following a trend in one way or another. Whether they make money doing it, of course, is another question altogether.

Regardless of your time horizon — minutes or months — a financial instrument must move in your favor to be profitable. It is that simple. So finding a reliable indicator to measure trend could be critical to your success.

As it turns out, there is a simple, quantitative indicator we can use to find stocks with the propensity for a big move…

It’s called relative strength (RS).

What Is Relative Strength (RS)?

Relative strength investing is pretty straightforward. It involves buying the best-performing stocks relative to all other stocks. We then hold these stocks until their momentum changes course.

To most investors, especially “value-minded” investors, this strategy probably feels counterintuitive. After all, one of the first things you learn as an investor is to “buy low, sell high.” But what we feel and what we can prove are two very different things. And there are decades of research to prove the predictive power of this indicator.

Top Performing Stocks To Buy For 2022: Blue Capital Reinsurance Holdings Ltd.(BCRH)

Blue Capital Reinsurance Holdings Ltd., incorporated on June 24, 2013, is an exempted limited liability company. Through its subsidiaries, the Company provides collateralized reinsurance in the property catastrophe market and invests in various insurance-linked securities. The Company’s wholly owned subsidiaries include Blue Capital Re, which is a Bermuda exempted limited liability company registered as a Class 3A insurer in Bermuda and provides collateralized reinsurance and Blue Capital Re ILS, which is a Bermuda exempted limited liability company that conducts hedging and other investment activities, including entering into industry loss warranties and purchasing catastrophe bonds operations.

As of December 31, 2014, the Company had $201.3 million of consolidated total assets. Blue Capital Re provides reinsurance to third-party insurance and reinsurance companies through reinsurance contracts, either directly with the cedant or on a fronted basis. Blue Capital Re also provides facultative retrocessional reinsurance to Blue Water Re.

The Company competes with Aeolus Capital Management; CatCo; Credit Suisse Asset Management; Leadenhall Capital; Lloyd’s of London; Nephila Capital Ltd.; Pillar Capital; RenaissanceRe Holdings Ltd. and Validus Holdings, Ltd.

Advisors’ Opinion:

  • [By Stephan Byrd]

    RLI (NYSE: BCRH) and Blue Capital Reinsurance (NYSE:BCRH) are both finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, earnings and institutional ownership.

  • [By Max Byerly]

    News articles about Blue Capital Reinsurance (NYSE:BCRH) have been trending somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Blue Capital Reinsurance earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news headlines about the insurance provider an impact score of 47.9769004082468 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

  • [By Shane Hupp]

    Blue Capital Reinsurance (NYSE:BCRH) reached a new 52-week high and low during trading on Thursday . The company traded as low as $10.90 and last traded at $11.05, with a volume of 17133 shares trading hands. The stock had previously closed at $11.20.

Top Performing Stocks To Buy For 2022: Alnylam Pharmaceuticals Inc.(ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its core product programs under clinical or pre-clinical development include ALN-TTR, a Phase I clinical trial program for the treatment of transthyretin-mediated amyloidosis; ALN-APC, a Phase I clinical trial program for the treatment of hemophilia; ALN-PCS for the treatment of severe hypercholesterolemia; ALN-HPN, a pre-clinical development for the treatment of refractory anemia; and ALN-TMP, a pre-clinical development for the treatment of hemoglobinopathies, including beta-thalassemia and sickle cell anemia. The company?s partner-based programs comprise ALN-RSV01, a Phase II clinical trial program for the treatment of respiratory syncytial virus infection; ALN-VSP, a Phase I clinical trial completed program for the treatment of liver cancers; and ALN-HTT, a pre-clinical development for the treatment of Huntington?s disease. It has strategic alliances with Novartis Pharma AG; F. Hoffmann-La Roche Ltd; Takeda Pharmaceutical Company Limited; Isis Pharmaceuticals, Inc.; Medtronic Inc.; Kyowa Hakko Kirin Co., Ltd.; and Cubist Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Alnylam Pharmaceuticals (ALNY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Cory Renauer]

    Staying on top of every new drugmaker takes a lot more time than you probably have. That said,Alnylam Pharmaceuticals (NASDAQ:ALNY)andPfizer (NYSE:PFE) shareholders want to keep their eyes on young Eidos and its lead candidate. Here’s why.

  • [By Brian Orelli]

    Alnylam Pharmaceuticals (NASDAQ:ALNY) updated investors last month on how the launch of Onpattro, its first drug that was approved to treat transthyretin-mediated amyloidosis (ATTR), was going at the J.P. Morgan Healthcare Conference.

Top Performing Stocks To Buy For 2022: TravelCenters of America LLC(TA)

TravelCenters of America LLC operates and franchises travel centers primarily along the United States interstate highway system. The company offers diesel fuel and gasoline, and diesel exhaust fluid; and operates full service restaurants under the Iron Skillet and Country Pride brands, as well as quick service restaurants primarily under Arby’s, Burger King, Dunkin’ Donuts, Godfather’s Pizza, Pizza Hut, Popeye’s Chicken & Biscuits, Starbuck’s Coffee, Subway, and Taco Bell brand names. It also operates truck repair and maintenance facilities that offer maintenance and emergency repair, and road services, such as oil changes, wheel alignments, and tire repair; and specialty services, including diagnostics and repair of air conditioning, brakes, and electrical systems. In addition, the company provides RoadSquad, a roadside truck service program; RoadSquad Connect, a centralized call center; and RoadSquad OnSite, a service program, as well as operates travel stores that offer packaged food and snack items, beverages, non-prescription drug and beauty supplies, batteries, automobile accessories, and music and video products. Further, it offers additional driver services, including specialized business services, which include information center; Reserve-It parking program; a banking desk; Wi-Fi Internet access; video game room; a laundry area; private showers; exercise facilities; and a theater or big screen television room. The company serves long haul trucking fleets and their drivers, independent truck drivers, and motorists. As of August 4, 2015, it operated 256 convenient full-service locations under the TravelCenters of America and Petro Stopping Centers brands in 43 states of the United States and Canada. The company also operated gasoline/convenience stores primarily under the Minit Mart brand. TravelCenters of America LLC was founded in 1992 and is headquartered in Westlake, Ohio.

Advisors’ Opinion:

  • [By Stephan Byrd]

    TravelCenters of America LLC (NASDAQ:TA) – B. Riley upped their FY2018 earnings estimates for TravelCenters of America in a research note issued to investors on Wednesday, September 5th. B. Riley analyst B. Maher now anticipates that the specialty retailer will earn ($0.62) per share for the year, up from their previous forecast of ($0.70). B. Riley has a “Buy” rating and a $10.00 price target on the stock. B. Riley also issued estimates for TravelCenters of America’s Q4 2018 earnings at ($0.15) EPS.

  • [By Logan Wallace]

    TravelCenters of America (NASDAQ:TA) had its price objective lifted by Craig Hallum from $6.50 to $10.00 in a research note issued to investors on Wednesday, The Fly reports.

  • [By Shane Hupp]

    TransAlta Co. (TSE:TA) (NYSE:TAC) insider Douglas French purchased 1,000 shares of the stock in a transaction that occurred on Monday, August 20th. The stock was bought at an average cost of C$48.51 per share, with a total value of C$48,510.00.

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on TravelCenters of America (TA)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Performing Stocks To Buy For 2022: SmartFinancial, Inc.(SMBK)

SmartFinancial, Inc. operates as the bank holding company for the SmartBank and Cornerstone Community Bank that provide various banking services to individuals and corporate customers in the United States. The company offers various deposit products, including savings accounts, checking accounts, zero balance accounts, sweep accounts, certificates of deposit, time deposits, noninterest-bearing demand deposits, and interest-bearing demand deposits. It also provides loan products, such as commercial real estate loans, consumer real estate loans, construction and land development loans, commercial and industrial loans, and small business administration loans; and consumer and other loans, such as direct consumer installment loans, overdrafts and other revolving credit loans, and educational loans. In addition, the company offers e-banking services consisting of online bill payments, smart pay, e-statements, and mobile banking, as well as debit and credit cards. It provides its banking services through 10 branches located in Eastern Tennessee; 2 branches located in the Florida Panhandle; and a loan production office each in Dalton, Georgia, and Panama City, Florida. SmartFinancial, Inc. is based in Knoxville, Tennessee.

Advisors’ Opinion:

  • [By Max Byerly]

    BidaskClub lowered shares of SmartFinancial (NASDAQ:SMBK) from a hold rating to a sell rating in a research note published on Thursday morning.

    A number of other analysts have also weighed in on SMBK. Zacks Investment Research upgraded SmartFinancial from a sell rating to a buy rating and set a $21.00 target price on the stock in a research note on Wednesday, January 16th. FIG Partners began coverage on SmartFinancial in a report on Friday, February 22nd. They issued an outperform rating for the company. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. The company has an average rating of Hold and an average price target of $24.60.

  • [By Stephan Byrd]

    Media coverage about SmartFinancial (NASDAQ:SMBK) has been trending somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. SmartFinancial earned a coverage optimism score of 0.16 on Accern’s scale. Accern also assigned news stories about the bank an impact score of 45.289677526379 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.